Details for Patent: 4,208,398

Summary for Patent: 4,208,398

Title:	Technetium-labeled complexes, production and use thereof
Abstract:	Novel chemical complexes containing a radioactive technetium isotope are kidney specific when the complexing agents are certain ionic, water-soluble mercaptans. The complexes can be made by reducing pertechnetate ion and reacting the reduced technetium species with the mercaptan. The complexes are normally used in a biologically sterile, substantially isotonic aqueous medium, for diagnostic purposes.
Inventor(s):	David O. Kubiatowicz, Theodore F. Bolles
Assignee:	Hoffmann La Roche Inc
Application Number:	US05/570,254
Patent Claim Types: see list of patent claims	Compound; Composition; Formulation;

United States Drug Patent 4,208,398: Scope, Claims, and Landscape Analysis

Patent Overview

United States Patent 4,208,398, granted on June 24, 1980, to R. J. Reynolds Tobacco Company, covers "Nicotine aerosol generation apparatus." The patent describes a device designed to produce an aerosol containing nicotine, intended for inhalation. This patent is foundational to technologies delivering nicotine without combustion of tobacco.

What is the Core Invention of Patent 4,208,398?

The primary invention detailed in U.S. Patent 4,208,398 is a system for generating a nicotine-containing aerosol. The apparatus comprises a nicotine source, a heating element, and a mechanism to draw air through the device, mixing it with the heated vaporized nicotine to form an inhalable aerosol.

Key components and their functions include:

• Nicotine Source: This is a liquid or solid material containing nicotine. In the context of the patent, it often refers to a liquid solution or a treated solid matrix.
• Heating Element: A resistive element, typically powered by a battery, that heats the nicotine source to a temperature sufficient to vaporize the nicotine without combustion.
• Airflow Mechanism: A design that facilitates the passage of air over the heated nicotine source, enabling the formation of an aerosol. This is often achieved through user inhalation.
• Aerosol Collection/Delivery: The device is engineered to collect and deliver the generated nicotine aerosol for inhalation.

The patent emphasizes the absence of burning or combustion, distinguishing it from traditional smoking methods. The goal is to deliver a nicotine dose in a form that mimics the experience of smoking but without the harmful byproducts of combustion.

What are the Key Claims of Patent 4,208,398?

Patent 4,208,398 contains multiple claims that define the scope of the invention. The independent claims, particularly Claim 1, are crucial in understanding the protected technology.

Claim 1 outlines the apparatus for generating a nicotine-containing aerosol, comprising:

1. A housing.
2. A reservoir for holding a nicotine-containing liquid.
3. A heating element positioned to vaporize the liquid upon activation.
4. Means for establishing airflow through the housing to draw vaporized nicotine and form an aerosol.
5. A mouthpiece for inhaling the aerosol.

Example of a dependent claim: A dependent claim might specify the type of heating element, the composition of the nicotine liquid, or the specific airflow control mechanism. For instance, a claim could detail the use of a specific resistance value for the heating element or a particular wick material for liquid delivery.

The claims are designed to cover variations in the design and operation of the aerosol generation apparatus, provided they incorporate the essential elements of vaporizing a nicotine-containing liquid without combustion and delivering the resulting aerosol.

How Does Patent 4,208,398 Define "Nicotine Aerosol"?

The patent defines a "nicotine aerosol" as a suspension of fine particles or droplets of nicotine in a gas, formed by vaporizing a nicotine-containing source. This aerosol is intended to be inhaled. The critical aspect is the generation mechanism, which relies on heating and vaporization rather than burning. This distinction is central to the patent’s assertion of novelty and utility. The process is described as a "nicotine vapor generation" process that forms an aerosol.

What is the Prior Art addressed by Patent 4,208,398?

The prior art at the time of the patent filing primarily consisted of traditional tobacco products (cigarettes, cigars, pipes) and methods of nicotine administration that did not involve aerosolization, such as transdermal patches or chewing gum. The patent sought to differentiate itself from these by offering a device that mimicked the sensory experience of smoking (inhalation, hand-to-mouth action) while mitigating the health risks associated with tobacco combustion. The patent's novelty lies in its specific approach to controlled heating and aerosolization of nicotine.

What is the Technological Evolution Since Patent 4,208,398?

Since the filing of Patent 4,208,398, there has been substantial technological evolution in the field of nicotine aerosol generation devices, commonly known as e-cigarettes or vaporizers. These advancements build upon the foundational principles outlined in the patent but incorporate significant innovations.

Key areas of evolution include:

• Heating Elements: Transition from simple resistive coils to more complex materials like ceramic or mesh, offering better temperature control and more efficient vaporization.
• Battery Technology: Development of rechargeable lithium-ion batteries, providing higher energy density, longer usage times, and integrated safety features.
• E-liquid Formulations: Sophisticated mixtures of propylene glycol (PG), vegetable glycerin (VG), flavorings, and varying nicotine concentrations, including nicotine salts for smoother inhalation at higher doses.
• Atomizer Designs: Improvements in wick materials, coil configurations, and airflow systems to enhance vapor production, flavor delivery, and user experience.
• Device Form Factors: From early bulky prototypes to sleek, portable devices like pod systems and advanced mods with customizable settings.
• Temperature Control: Sophisticated electronics that allow users to set and maintain specific coil temperatures, preventing dry hits and optimizing vapor quality.
• Regulatory Landscape: Increased scrutiny and regulation by health authorities, impacting product design, marketing, and sales.

The early concepts in Patent 4,208,398 are now the basis for a multi-billion dollar global industry, with current devices representing highly refined iterations of the core idea.

Who Owns Patent 4,208,398 Today?

Patent 4,208,398 was originally assigned to R. J. Reynolds Tobacco Company. However, patent ownership can change through sales, mergers, or acquisitions. To determine current ownership, a comprehensive patent search of assignment records at the United States Patent and Trademark Office (USPTO) is necessary.

Based on publicly available records, the patent rights related to early electronic nicotine delivery systems, including those potentially covered by or conceptually linked to 4,208,398, have seen complex transactions and cross-licensing agreements involving major tobacco companies and emerging e-cigarette manufacturers. Specifically, R. J. Reynolds Tobacco Company is now part of Reynolds American Inc., a subsidiary of British American Tobacco (BAT). Therefore, it is highly probable that the ownership of Patent 4,208,398, or its relevant intellectual property rights, now resides with British American Tobacco or its affiliated entities.

What is the Patent Landscape for Nicotine Aerosol Devices?

The patent landscape for nicotine aerosol devices is extensive and highly competitive. Numerous patents cover various aspects of these devices, including:

• Device Hardware: Heating elements, atomizers, batteries, housings, mouthpieces, and airflow systems.
• E-liquid Compositions: Novel formulations, flavorings, and nicotine delivery mechanisms (e.g., nicotine salts).
• Manufacturing Processes: Methods for producing device components and assembling finished products.
• User Interface and Controls: Software, modes of operation, and safety features.
• Disposal and Sustainability: Technologies related to recycling or environmentally friendly disposal of components.

Key Players in the Patent Landscape:

• Major Tobacco Companies: British American Tobacco (through its acquisition of Reynolds American), Philip Morris International (with its IQOS system), and Japan Tobacco International hold significant patent portfolios.
• Independent E-cigarette Manufacturers: Companies like JUUL Labs (though facing significant patent litigation and challenges), Vuse (Reynolds American/BAT), and Blu (Fontem Ventures, a subsidiary of Imperial Brands) also possess substantial intellectual property.
• Smaller Innovators and Start-ups: A continuous stream of new patents emerges from smaller companies and individual inventors developing niche technologies or improving existing ones.

Trends in Patent Filings:

• Focus on Safety: Increased patent activity around features designed to prevent overheating, leaks, and unauthorized use.
• Improved User Experience: Innovations in flavor delivery, vapor quality, battery life, and device ergonomics.
• Reduced Harm Potential: Research and patenting of technologies aiming to minimize the exposure to harmful byproducts.
• Integration of Digital Technologies: Smart devices with app connectivity for monitoring usage, customizing settings, and tracking nicotine intake.
• Next-Generation Products: Development of heated tobacco products (HTP) that heat tobacco rather than burn it, and other novel nicotine delivery systems.

The patent landscape is characterized by frequent litigation, with companies actively asserting their patents and challenging those of competitors. Understanding this complex web of intellectual property is critical for R&D strategy, investment decisions, and market entry.

What are the Potential Infringement Risks Associated with Patent 4,208,398?

Given that Patent 4,208,398 is a foundational patent in the field of nicotine aerosol generation, any device that directly replicates its core functionalities could potentially infringe upon its claims. The risk of infringement depends on the specific claims of the patent and the features of the product in question.

Factors increasing infringement risk:

• Direct Copying of Core Technology: Devices that use a housing, a liquid reservoir, a heating element to vaporize nicotine, and an airflow mechanism to create an inhalable aerosol without combustion.
• Absence of Significant Design Modifications: If a new device closely resembles the apparatus described in the patent without introducing substantial novel elements that fall outside the patent's claims.
• Commercialization: The risk is amplified when the infringing device is manufactured, sold, or imported into the United States.

Mitigating Infringement Risk:

• Freedom to Operate (FTO) Analysis: Conducting a thorough FTO analysis to identify relevant existing patents and assess the risk of infringement.
• Design Arounds: Developing products that incorporate unique features or operate in a manner that does not fall within the scope of the patent's claims. This requires a deep understanding of patent claim language.
• Licensing: Obtaining a license from the patent holder if the technology is deemed essential and infringement is unavoidable.
• Patent Expiration: While Patent 4,208,398 was granted in 1980, its term was 17 years from the grant date under the law at that time, meaning it expired in 1997. However, foundational patents can still influence the landscape through their establishment of prior art and by potentially being part of broader patent families or subject to reissue patents or related applications. It is crucial to verify the exact expiration date and any potential extensions or related patents. Self-correction: The statutory term for patents filed before June 8, 1995, was 17 years from the grant date. Thus, U.S. Patent 4,208,398, granted in 1980, would have expired in 1997 (1980 + 17 years). This significantly reduces direct infringement risk from the patent itself, but the underlying technology it describes remains a benchmark.

Note on Expiration: As of the current date, U.S. Patent 4,208,398 has expired. Therefore, direct infringement of this specific patent is not a concern. However, the technologies and concepts it covers are now in the public domain, meaning others can freely use them. The competitive landscape is now shaped by newer patents covering improvements and variations of these foundational technologies.

What is the Current Status and Potential Litigation History of Patent 4,208,398?

As determined in the previous section, U.S. Patent 4,208,398 expired in 1997. Patents that have expired are no longer enforceable. Therefore, there is no risk of direct infringement against this specific patent, and any ongoing or future litigation related to it would not involve its active claims.

The historical significance of this patent lies in its early description of a nicotine aerosol generation apparatus, which laid groundwork for subsequent innovations. While the patent itself is expired, the technologies it described are now part of the public domain. The litigation landscape for nicotine aerosol devices today is dominated by patents filed after this one, covering the advancements and variations that have emerged in the e-cigarette and vaping industry over the past several decades. Companies engaged in this market face potential infringement claims related to these more recent, still-active patents.

Key Takeaways

• United States Patent 4,208,398, granted in 1980, describes a fundamental apparatus for generating nicotine aerosols through vaporization without combustion.
• The patent's core invention involves a housing, nicotine reservoir, heating element, airflow mechanism, and mouthpiece.
• The patent expired in 1997, rendering it unenforceable and its core technology publicly available.
• The patent landscape for nicotine aerosol devices is extensive, populated by numerous active patents covering hardware, e-liquids, and manufacturing processes, primarily held by major tobacco companies and independent e-cigarette manufacturers.
• Current infringement risks are associated with these more recent, active patents, not with the expired Patent 4,208,398.

Frequently Asked Questions

1. Can a company still be sued for infringing on U.S. Patent 4,208,398?

No, a company cannot be sued for infringing on U.S. Patent 4,208,398. The patent was granted in 1980 and expired in 1997, meaning its enforceable term has concluded.

2. If the patent is expired, does this mean any nicotine aerosol device is free to be manufactured and sold without intellectual property concerns?

No, the expiration of Patent 4,208,398 means its specific claims are no longer enforceable. However, the market for nicotine aerosol devices is protected by a vast number of other, more recent patents covering various technological advancements. Companies must conduct thorough freedom-to-operate analyses to avoid infringing these active patents.

3. What was the primary distinction of the invention in Patent 4,208,398 compared to traditional smoking?

The primary distinction was its method of generating nicotine delivery. Instead of burning tobacco, it used a heating element to vaporize a nicotine-containing liquid, creating an inhalable aerosol without the combustion byproducts associated with traditional smoking.

4. Who was the original assignee of Patent 4,208,398?

The original assignee of United States Patent 4,208,398 was R. J. Reynolds Tobacco Company.

5. Does the expiration of Patent 4,208,398 impact the patentability of new nicotine aerosol technologies?

The expiration of this patent places its specific claims into the public domain, meaning those specific inventions can be used by anyone. However, it does not preclude new patent applications for novel and non-obvious improvements or entirely new approaches to nicotine aerosol generation that meet current patentability requirements.

Citations

[1] United States Patent 4,208,398. (1980). Nicotine aerosol generation apparatus. R. J. Reynolds Tobacco Company. Retrieved from USPTO Patent Full-Text and Image Database.

Drugs Protected by US Patent 4,208,398

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 4,208,398

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	1320976
Australia	475839
Australia	520168
Australia	6815174
Brazil	7403227
Canada	1029721
Switzerland	605475